Pharmacovigilance reporting during seasonal malaria chemoprevention campaign: Findings from northern Nigeria

Aiden, Jimmy; Dabes, Chrysanthus; Maduka, Kenneth; Oguche, Daniel; Itiola, Ademola Joshua; Oresanya, Olusola

doi:10.1016/j.sciaf.2022.e01283

Cited by 2 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…External environmental factors do influence the survival and the persistence of vectors and subsequently, enhance the transmission of their respective Plasmodium species. Factors promoting transmissions may include seasonal changes with a high prevalence of malaria cases and deaths linked to the wet season in most of Africa [107,135,136]. Mosquito populations and bites increase due to enabling conditions that facilitate the breeding of the vector throughout the wet period and summer [57,105].…”

Section: Environmental Impact Of Plasmodium Transmissionmentioning

confidence: 99%

One Health Perspective of Malaria Transmission

Bedford Danquah,

Afua Afrifa Yamoah

2024

Infectious Diseases

View full text Add to dashboard Cite

Global efforts towards malaria control and elimination are promising. Despite this, current alterations in transmission continue to modify and frustrate such effort. In 2020 and 2021, malaria transmissions increased significantly. While 2021 showed a decline in malaria deaths by 6000 (1%), the numbers were still 51,000 (9%) higher than malaria deaths in 2019. Two-thirds of the contributing factors were attributed to the COVID-19 pandemic, thus demonstrating the capability of future pandemics and zoonotic diseases to stagger or derail earned achievements towards malaria elimination. Compounded by zoonotic and environmental factors that promote malaria transmission, there will be a need for relevant modelling and an update on current and past disease distribution information and will also be required to shape policy actions and to improve public health decision-making on malaria. These will help strengthen the evidence for the adoption of relevant implementation strategies to aid the 2030 vision of eliminating malaria a reality.

show abstract

Section: Environmental Impact Of Plasmodium Transmissionmentioning

confidence: 99%

One Health Perspective of Malaria Transmission

Bedford Danquah,

Afua Afrifa Yamoah

2024

Infectious Diseases

View full text Add to dashboard Cite

show abstract

Spontaneous adverse drug reaction reporting during the seasonal malaria chemoprevention campaign in 2022

Rotimi,

Fagbemi,

Ibinaiye

et al. 2023

Bull Natl Res Cent

View full text Add to dashboard Cite

Background Seasonal administration of antimalaria drug, sulphadoxine/pyrimethamine plus amodiaquine to children 3–59 months is a malaria preventive intervention used for the reduction of childhood malaria morbidity and mortality in area with highly seasonal malaria transmission like sub-Saharan Africa. This intervention has been deployed in Nigeria and other sub-Saharan African countries for years and may continue for more years to come either alone or combination with other novel interventions. Despite the importance of pharmacovigilance, there is currently a dearth of pharmacovigilance data in most African countries, especially in public health interventions like seasonal malaria chemoprevention campaigns. The availability of quality safety data is likely to improve the acceptability of this preventive intervention. Results The study identified vomiting as the most reported adverse drug reaction. Other reported reactions include weakness, fever, abdominal pain, convulsion, redness of the eyes, swollen hand/face, rash, itching, cough, headache, and excessive salivation. Using Naranjo scale, 69.2% of the reported reactions can be classified as possible; while 29.5% can be classified as probable, only 1.3% is classified as definite. 92.3% of reported adverse drug reactions were from children 12–59 months and 7.7% were from those 3–11 months. The proportion of ADRs classified according to the affected organ/system is as follows: central nervous system (10.26%), gastrointestinal (60.26%), ocular (10.26%), musculoskeletal (7.69%), and dermatological (11.53%). The study also suggests better tolerability to the seasonal malaria chemoprevention medicines with more implementation experience, as states with more implementation experiences reported fewer suspected adverse drug reactions. Conclusions The findings from this study provide additional information on possible adverse drug reactions during seasonal malaria chemoprevention campaigns. This additional information should be communicated to caregivers during the seasonal malaria chemoprevention campaigns as a way of building trust and improving acceptability of the intervention. Also, strengthening of the national pharmacovigilance system is vital to ensure improved timeliness, quality, and quantity of pharmacovigilance reporting on SMC intervention in Africa, as results from the study show low levels of pharmacovigilance reporting across the states.

show abstract

Pharmacovigilance reporting during seasonal malaria chemoprevention campaign: Findings from northern Nigeria

Cited by 2 publications

References 16 publications

One Health Perspective of Malaria Transmission

One Health Perspective of Malaria Transmission

Spontaneous adverse drug reaction reporting during the seasonal malaria chemoprevention campaign in 2022

Contact Info

Product

Resources

About